To explore whether targeting the TFs mentioned above represents a therapeutic opportunity in GBM, we performed the pharmacological inhibition of AP‐1, RUNX1 and RUNX2 with the respective available chemical inhibitors T‐5224, Ro5‐3335 and CADD522. This evidence concerns the gene JUN and glioblastoma.